Recurrent C. diff infections linked to higher death rates, research shows Clostridium difficile infection recurrence may increase the risk of death in patients, according to a presentation at the 27th ...

Panelist discusses how recurrent Clostridioides difficile infection results from persistent microbiome disruption, where antibiotic-induced dysbiosis enables bacterial overgrowth and toxin production.

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Rebyota's FDA approval was based on clinical trial data showing significant reduction in CDI recurrence rates compared to placebo. The pivotal trial was a randomized, double-blind, placebo-controlled ...

Please provide your email address to receive an email when new articles are posted on . However, this finding did not reach statistical significance, the researchers noted. “This is the first ...

SAN DIEGO -- Administering fecal microbiota via colonoscopy instead of rectally prevented recurrence of Clostridium difficile (C. diff) for up to 2 months with no major safety signals, according to a ...

ATLANTA -- A tapered and pulsed course of vancomycin was not significantly better than a standard course of the drug for treating a first or second recurrence of Clostridioides difficile infection, a ...

AstraZeneca (AZN) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed ...

A single fecal transplantation is not more effective than the existing standard of care — administration of oral vancomycin taper — for treating patients with recurrent Clostridium difficile infection ...

PHILADEPHIA — Both initial and sustained responses to fecal microbiota transplant (FMT) for the treatment of refractory C difficile infection remain high out to 18 months' follow-up, provided patients ...

WEST LAFAYETTE, Ind. – Clostridioides difficile, or C. diff, is the leading cause of health care-associated infection in the U.S. Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for ...

AstraZeneca (AZN) announced an update on their ongoing clinical study. AstraZeneca is running a Phase IIb study titled “A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the ...